Oncology

Latest News

Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com

Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

By Jared Kaltwasser

June 19th 2025

Median overall survival was 5 months longer in patients with small cell lung cancer (SCLC) who received tarlatamab instead of chemotherapy after progression following platinum-based chemotherapy.

The data presented at ASCO reflect patients seen during 2 community health fairs designed to reach underserved populations in Georgia. | Image credit: NIKCOA - stock.adobe.com

Teledermatology Shows Promise to Reduce Disparities in Skin Cancer Screening

By Jared Kaltwasser

June 18th 2025

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com

Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

By Jared Kaltwasser

June 13th 2025

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com

FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg

Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

By Giuliana Grossi

June 12th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

January 3rd 2017

First Patient Treated With Jakafi in Phase 2 Graft-Versus-Host Disease Study

The first patient has been treated with ruxolitinib (Jakafi), by Incyte Corporation, for steroid-refractory acute graft-versus-host disease, as part of the REACH-1 phase 2 trial. The trial is evaluating ruxolitinib in combination with corticosteroids.

Dr Carrie Stricker Discusses the Importance of the Patient Voice in Oncology Treatment Decisions

January 2nd 2017

Dr Carrie Stricker Discusses the Importance of the Patient Voice in Oncology Treatment Decisions

Oncologists must recognize the importance of the patient voice when making treatment decisions so that the treatment plan can be adapted to each patient’s goals and desires, said Carrie Stricker, PhD, RN, AOCN, chief clinical officer and co-founder of Carevive.

Pam Mangat Discusses ASCO's Progress on TAPUR Study

January 1st 2017

Pam Mangat Discusses ASCO's Progress on TAPUR Study

The TAPUR clinical trial is rapidly expanding to new sites, but the researchers have not yet collected enough data to analyze and publish the results, according to Pam Mangat, MS, associate director TAPUR study at the American Society of Clinical Oncology.

December 31st 2016

Examining the Uterine Lavage Fluid for Early Signs of Endometrial Cancer

Surabhi Dangi-Garimella, PhD

According to a new study published in PLOS Medicine, genetic analysis of the uterine lavage fluid from pre- and post-menopausal women can provide early evidence of endometrial cancer.

December 30th 2016

Conference Stories That Captivated AJMC® Readers in 2016

Surabhi Dangi-Garimella, PhD

A glimpse at the top 5 articles from The American Journal of Managed Care'sÂ® conference coverage that caught reader attention in 2016.

December 29th 2016

Midwestern States Witness Significant Increase in Melanoma Deaths Over a Decade

Surabhi Dangi-Garimella, PhD

Twenty-three of 48 states in the United States saw a drop in melanoma—associated death in 2013 compared with 2003, while 21 states witnessed a rise in the death rate.

Samantha Watson Discusses Cancer's Financial Impact on Young Adults

December 29th 2016

Samantha Watson Discusses Cancer's Financial Impact on Young Adults

Cancer care and its associated costs can combine with everyday bills to create a significant financial burden, especially for young adults with cancer, said Samantha Watson, founder and CEO of The Samfund.

December 28th 2016

Reducing Radiation Dose in Oropharynx Cancer Can Improve QOL

Surabhi Dangi-Garimella, PhD

A new clinical study to reduce the unwanted side effects of radiation in patients with human papillomavirus (HPV)—positive oropharynx cancers has found that reducing the dose of radiation can maintain the cure rates but avoid some of the late treatment-associated toxicities.

December 27th 2016

Most Popular News Stories on AJMC.com in 2016

Surabhi Dangi-Garimella, PhD

As 2016 draws to a close, here’s a look at the top 5 news articles that captured reader interest on AJMC.com.

Jonathan Hirsch on Making Data Usable for Oncologists at the Point of Care

December 26th 2016

Jonathan Hirsch on Making Data Usable for Oncologists at the Point of Care

Oncology care is often spread out across multiple facilities and providers, so health IT innovators use software to integrate data from these many locations and deliver it to the point of care, according to Jonathan Hirsch, founder and president of Syapse.

Dr Sean Khozin Discusses How FDA Regulatory Process Helps Advance Precision Oncology

December 24th 2016

Dr Sean Khozin Discusses How FDA Regulatory Process Helps Advance Precision Oncology

FDA’s regulatory science activities are working to advance the field of precision oncology, in part by using predictive analyses to identify patients that may be good candidates for certain therapies, according to Sean Khozin, MD, MPH, senior medical officer at the FDA.

December 23rd 2016

SWOG Trial Results Could Lead to New Standard of Care in Multiple Myeloma

Surabhi Dangi-Garimella, PhD

The Lancet study shows addition of bortezomib significantly improves survival in treatment-naÃ¯ve patients with multiple myeloma.

December 23rd 2016

Precision Treatment Would Benefit Patients With Glioblastoma, Stanford Analysis Finds

Surabhi Dangi-Garimella, PhD

Using angiogenesis inhibitors in patients with glioblastoma that is highly vascularized could yield much improved outcomes, the analysis found.

This Week in Managed Care: December 23, 2016

December 23rd 2016

This Week in Managed Care: December 23, 2016

This week, the top managed care stories included CMS announcing more mandatory bundled payment models and a new track in the Medicare Shared Savings Program, the FDA approving a new use for Dexcom's continuous glucose monitor, and a greater emphasis on lifestyle management in the American Diabetes Association's care standards.

Dr Stuart Goldberg on How to Collect Data in a Way That Makes Oncologic Sense

December 23rd 2016

Dr Stuart Goldberg on How to Collect Data in a Way That Makes Oncologic Sense

The kind of data oncologists need to move towards value-based care isn’t easily accessible in patient electronic health records, but new platforms like Cancer Outcomes Tracking and Analysis (COTA) are trying to make it easier, said Stuart Goldberg, MD, chief medical officer, COTA, John Theurer Cancer Center.

December 22nd 2016

Patient-Physician Communication Can Influence Decisions on CPM, Avoid Overtreatment

Surabhi Dangi-Garimella, PhD

A new study has found that women chose not to go ahead with contralateral prophylactic mastectomy (CPM) if their surgeon recommended against it.

December 22nd 2016

FDA Urges Researchers to Enroll Adolescents in Adult Oncology Trials

Surabhi Dangi-Garimella, PhD

Adolescents who have “adult-type” cancers should be enrolled in relevant clinical trials to improve access for this population of patients, experts from the FDA write in a recently published perspective.

December 21st 2016

Using a Tumor's Genomic Signature to Guide Radiation Therapy Doses

Surabhi Dangi-Garimella, PhD

Researchers at the Moffitt Cancer Center have developed a genomics model called genomic-adjusted radiation dose that can guide the radiation dose to match a tumor’s radiosensitivity.

December 20th 2016

Expert Insights: Most Popular Videos, Interviews, and Podcasts in 2016

Laura Joszt, MA

Along with the peer-review research, journal articles, and news coverage, The American Journal of Managed Careâ„¢ (AJMCâ„¢) has a robust multimedia component that brings together stakeholders from across the healthcare industry to discuss important topics in the world of managed care and delve deeper into topics.

December 20th 2016

Will the FDA Replicate the Oncology Center of Excellence?

Surabhi Dangi-Garimella, PhD

The 21st Century Cures Act mandates the creation of "one or more" intercenter institutes at the FDA. But is such a massive reorganization feasible within the FDA?

December 19th 2016

First NGS-Based Companion Diagnostic Approved With Rucaparib for Advanced Ovarian Cancer

The FDA has provided accelerated approval for rupacarib along with the first next-generation sequencing—based companion diagnostic test, for the treatment of women with advanced ovarian cancer.

December 19th 2016

Most Popular Articles in Evidence-Based Oncologyâ„¢ in 2016

Surabhi Dangi-Garimella, PhD

Here's a look at some of the most popular articles published in Evidence-Based Oncologyâ„¢ in 2016.

December 19th 2016

Will a Payer-Provider Collaboration Guarantee OCM Success?

Surabhi Dangi-Garimella, PhD

At the Payer Exchange Summit V, in Tyson’s Corner, Virginia, oncologists and payers came together to discuss the role of collaboration and data sharing for the successful implementation of the Oncology Care Model (OCM).

Dr Joseph Alvarnas Discusses Clinical Risk in Value-Based Cancer Care

December 18th 2016

Dr Joseph Alvarnas Discusses Clinical Risk in Value-Based Cancer Care

The new era of data informatics tools can help providers and payers understand the tiers of risk that determine the economics of care delivery, which is crucial to value-based cancer treatment, according to Joseph Alvarnas, MD, of the City of Hope and editor-in-chief of Evidence-Based Oncology

December 16th 2016

CMS Decision to Abandon Medicare Part B Demo Greeted With Sighs of Relief

Christina Mattina

After widespread criticism from healthcare providers, drug companies, and lawmakers, CMS has announced that it will not go forward with its proposed Medicare Part B payment program. The experimental reimbursement model was intended to reduce outpatient drug spending, but oncologists worried it would have unfairly slashed their Part B payments.

This Week in Managed Care: December 16, 2016

December 16th 2016

This Week in Managed Care: December 16, 2016

This week, the top stories in managed care include President Barack Obama signing the 21st Century Cures Act into law, findings from the CDC that opioid abuse has reduced life expectancy for Americans, and CVS announced a new program to lower costs for patients with diabetes.

December 16th 2016

Craig Sager Loses His Fight Against AML

Surabhi Dangi-Garimella, PhD Mary Caffrey

Craig Sager, a sideline reporter for CNN and Turner Sports, has died a little over 2 and a half years after being diagnosed with acute myeloid leukemia (AML).

December 15th 2016

Strategies for OCM Implementation at the COA Payer Summit

Surabhi Dangi-Garimella, PhD

At the Community Oncology Alliance (COA) Payer Exchange Summit V, panelists provided insights for successful implementation of payment models in oncology clinics.

December 15th 2016

How Can Practices Seek Success With Oncology Payment Reform?

Surabhi Dangi-Garimella, PhD

Bruce Gould, MD, president and medical director, Northwest Georgia Oncology Center, and president of the Community Oncology Alliance, presented an overview of how cancer care has improved over the years and what the current challenges are.

Jonathan Hirsch: How Syapse Uses Health IT to Implement Precision Medicine

December 15th 2016

Jonathan Hirsch: How Syapse Uses Health IT to Implement Precision Medicine

Implementing precision medicine is a complex undertaking that cannot be accomplished without the use of health IT tools, according to Jonathan Hirsch, founder and president of Syapse. He identified the 4 key functions of healthcare IT that allow Syapse to expand access to precision medicine.

...

85 86 87 88 89 90 91 92 93

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions